Clinical Trials
32 trialsPRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
SIB
Medical College of Wisconsin
AWARE
Rigshospitalet, Denmark
PEGASUS
European Organisation for Research and Treatment of Cancer - EORTC
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
RADVAN
Sun Yat-sen University
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Weill Medical College of Cornell University
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
Mayo Clinic
REVELUTION
Emory University
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
STEEL
RTOG Foundation, Inc.
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
DECREASE
Trans Tasman Radiation Oncology Group
PRORAD
Erasmus Medical Center
OLIGOPELVIS2
Institut Cancerologie de l'Ouest
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
IOSCAR
Istituto Clinico Humanitas
ADOPT
University Medical Center Groningen
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
University of California, San Francisco
IP2-ATLANTA
Imperial College London
PCS IV
Université de Sherbrooke
PEACE1
UNICANCER
MEDCARE
Universitaire Ziekenhuizen KU Leuven